Trifluridine/tipiracil (TAS-102) in combination with anti-EGFR re-challenge versus TAS-102 plus anti-VEGF in patients with mCRC who experienced first-line anti-EGFR-based chemotherapy.

Authors

Ching Tso Chen

Department of Oncology, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan

Ching Tso Chen , Yi-Hsin Liang , Kun-Huei Yeh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Phase III FIRE-4 study (AIO KRK-0114): Evaluation of first-line treatment efficacy of FOLFIRI/cetuximab in patients with RAS-WT mCRC receiving the first cycle of treatment with chemotherapy only.

First Author: Sebastian Stintzing

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Right-sided colorectal cancer (RC): Response to first-line chemotherapy in FIRE-3 (AIO KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DpR).

First Author: Julian Walter Holch

insert_chart_outlined

Poster

2013 Gastrointestinal Cancers Symposium

bookmark_border

Predictive value of baseline CD66e/CEA serum levels on efficacy of bevacizumab-based treatment in advanced colorectal cancer.

First Author: Gerald Prager

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer.

First Author: Yijiao Chen